LVIS Corporation has launched NeuroMatch Access, an artificial-intelligence (AI)-driven platform for electroencephalogram (EEG) data analysis in the US.
The Silicon Valley, US-based company’s platform, which received 510(k) clearance from the US Food and Drug Administration (FDA) in May 2023, uses AI to review and interpret EEG signals by removing unwanted artifacts.
EEG is used to measure electrical activity of the brain and can aid in the diagnosis of conditions including brain damage and epilepsy.
NeuroMatch Access is intended to speed-up and improve the efficiency of clinical workflows by providing real-time visualisations of brain circuits to support diagnosis and the planning of targeted care strategies for brain conditions.
"NeuroMatch represents a transformative step towards democratising neurological care for patients worldwide,” said LVIS founder Dr Jin Hyung Lee.
"Our commitment is to harness advanced technology to not only expedite EEG diagnostics but also to make these critical services accessible to all.”
Earlier this year, LVIS rolled NeuroMatch out in 10 hospitals across South Korea, with the company also launching its first NeuroMatch Center, an educational hub located in the South Korean city of Daegu, in June 2024. The hub features monitoring rooms for EEG diagnostics and a lecture hall for training healthcare professionals.
According to GlobalData analysis, the global electrical activity testing segment of the neurology devices market was valued at around $1.29bn in 2023 and is forecast to reach a valuation of around $1.52bn by 2033.
A 2023 Market Model methodology by GlobalData found that Nihon Kohden was the biggest player in the $200m US electrical activity testing market, followed by Natus Medical and Medtronic.
Elsewhere in EEG, Natus sought FDA clearance for its point-of-care EEG device in October 2024, while Zeto gained FDA clearance for Zeto ONE, an EEG headset and workflow management platform, in June.
